190 related articles for article (PubMed ID: 19604121)
1. Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin.
Boulikas T
Expert Opin Investig Drugs; 2009 Aug; 18(8):1197-218. PubMed ID: 19604121
[TBL] [Abstract][Full Text] [Related]
2. Liposomal cisplatin: a new cisplatin formulation.
Stathopoulos GP
Anticancer Drugs; 2010 Sep; 21(8):732-6. PubMed ID: 20671511
[TBL] [Abstract][Full Text] [Related]
3. Systemic Lipoplatin infusion results in preferential tumor uptake in human studies.
Boulikas T; Stathopoulos GP; Volakakis N; Vougiouka M
Anticancer Res; 2005; 25(4):3031-9. PubMed ID: 16080562
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study.
Jehn CF; Boulikas T; Kourvetaris A; Possinger K; Lüftner D
Anticancer Res; 2007; 27(1A):471-5. PubMed ID: 17352269
[TBL] [Abstract][Full Text] [Related]
5. First safety and response results of a randomized phase III study with liposomal platin in the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN).
Jehn CF; Boulikas T; Kourvetaris A; Kofla G; Possinger K; Lüftner D
Anticancer Res; 2008; 28(6B):3961-4. PubMed ID: 19192656
[TBL] [Abstract][Full Text] [Related]
6. Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts.
Boulikas T
Oncol Rep; 2004 Jul; 12(1):3-12. PubMed ID: 15201951
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study.
Stathopoulos GP; Boulikas T; Vougiouka M; Deliconstantinos G; Rigatos S; Darli E; Viliotou V; Stathopoulos JG
Oncol Rep; 2005 Apr; 13(4):589-95. PubMed ID: 15756428
[TBL] [Abstract][Full Text] [Related]
8. Low renal toxicity of lipoplatin compared to cisplatin in animals.
Devarajan P; Tarabishi R; Mishra J; Ma Q; Kourvetaris A; Vougiouka M; Boulikas T
Anticancer Res; 2004; 24(4):2193-200. PubMed ID: 15330160
[TBL] [Abstract][Full Text] [Related]
9. Activity of lipoplatin in tumor and in normal cells in vitro.
Arienti C; Tesei A; Ravaioli A; Ratta M; Carloni S; Mangianti S; Ulivi P; Nicoletti S; Amadori D; Zoli W
Anticancer Drugs; 2008 Nov; 19(10):983-90. PubMed ID: 18827563
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer.
Casagrande N; De Paoli M; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
Gynecol Oncol; 2013 Dec; 131(3):744-52. PubMed ID: 24029417
[TBL] [Abstract][Full Text] [Related]
11. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
[TBL] [Abstract][Full Text] [Related]
12. Liposomal cisplatin dose escalation for determining the maximum tolerated dose and dose-limiting toxicity: a phase I study.
Stathopoulos GP; Rigatos SK; Stathopoulos J
Anticancer Res; 2010 Apr; 30(4):1317-21. PubMed ID: 20530446
[TBL] [Abstract][Full Text] [Related]
13. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
14. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin and platinum drugs at the molecular level. (Review).
Boulikas T; Vougiouka M
Oncol Rep; 2003; 10(6):1663-82. PubMed ID: 14534679
[TBL] [Abstract][Full Text] [Related]
16. Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model.
Harrington KJ; Rowlinson-Busza G; Syrigos KN; Vile RG; Uster PS; Peters AM; Stewart JS
Clin Cancer Res; 2000 Dec; 6(12):4939-49. PubMed ID: 11156255
[TBL] [Abstract][Full Text] [Related]
17. A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin.
Veal GJ; Griffin MJ; Price E; Parry A; Dick GS; Little MA; Yule SM; Morland B; Estlin EJ; Hale JP; Pearson AD; Welbank H; Boddy AV
Br J Cancer; 2001 Apr; 84(8):1029-35. PubMed ID: 11308249
[TBL] [Abstract][Full Text] [Related]
18. Lipoplatin monotherapy: A phase II trial of second-line treatment of metastatic non-small-cell lung cancer.
Ravaioli A; Papi M; Pasquini E; Marangolo M; Rudnas B; Fantini M; Nicoletti SV; Drudi F; Panzini I; Tamburini E; Gianni L; Pasini G
J Chemother; 2009 Feb; 21(1):86-90. PubMed ID: 19297279
[TBL] [Abstract][Full Text] [Related]
19. Intrapleural administration of lipoplatin in an animal model.
Froudarakis ME; Greillier L; Monjanel-Mouterde S; Koutsopoulos A; Devictor-Pierre B; Guilhaumou R; Karpathiou G; Botaitis S; Astoul P
Lung Cancer; 2011 Apr; 72(1):78-83. PubMed ID: 20728238
[TBL] [Abstract][Full Text] [Related]
20. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice.
Kim JH; Kim YS; Park K; Lee S; Nam HY; Min KH; Jo HG; Park JH; Choi K; Jeong SY; Park RW; Kim IS; Kim K; Kwon IC
J Control Release; 2008 Apr; 127(1):41-9. PubMed ID: 18234388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]